MA53991A - Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations - Google Patents

Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations

Info

Publication number
MA53991A
MA53991A MA053991A MA53991A MA53991A MA 53991 A MA53991 A MA 53991A MA 053991 A MA053991 A MA 053991A MA 53991 A MA53991 A MA 53991A MA 53991 A MA53991 A MA 53991A
Authority
MA
Morocco
Prior art keywords
fusion proteins
esterase inhibitor
inhibitor fusion
esterase
proteins
Prior art date
Application number
MA053991A
Other languages
English (en)
Inventor
Andrea Iskenderian
Angela Norton
Clark Pan
Bettina Strack-Logue
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MA53991A publication Critical patent/MA53991A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
MA053991A 2014-10-31 2015-10-31 Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations MA53991A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462073657P 2014-10-31 2014-10-31

Publications (1)

Publication Number Publication Date
MA53991A true MA53991A (fr) 2021-09-15

Family

ID=54548264

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053991A MA53991A (fr) 2014-10-31 2015-10-31 Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations

Country Status (11)

Country Link
US (1) US20160130324A1 (fr)
EP (2) EP3769780A1 (fr)
JP (3) JP6740225B2 (fr)
KR (2) KR20170074244A (fr)
CN (2) CN113698495A (fr)
AU (2) AU2015338913B2 (fr)
BR (1) BR112017008962A2 (fr)
CA (1) CA2964132A1 (fr)
HK (1) HK1243443A1 (fr)
MA (1) MA53991A (fr)
WO (1) WO2016070156A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43270A (fr) * 2015-11-19 2021-06-02 Takeda Pharmaceuticals Co Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
JP2019534240A (ja) 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
CA3102086A1 (fr) * 2017-06-06 2018-12-13 Relinia, Inc. Proteines de fusion agonistes du recepteur 2 du tnf monocatenaire
WO2018233572A1 (fr) * 2017-06-20 2018-12-27 四川百利药业有限责任公司 Criblage de sites de couplage à point fixe d'un conjugué anticorps-toxine modifié par cystéine (tdc)
WO2020081328A1 (fr) * 2018-10-15 2020-04-23 The Regents Of The University Of California Cellules déficientes en composant 1s (c1s) du complément pour la production de vaccins et de protéines biopharmaceutiques
WO2020252136A1 (fr) * 2019-06-11 2020-12-17 Shire Human Genetic Therapies, Inc. Administration de vecteur viral adéno-associé d'anticorps pour le traitement de la kallicréine plasmatique dérégulée à médiation par une maladie
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
AU2021381360A1 (en) 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
WO1992022320A1 (fr) * 1991-06-14 1992-12-23 Genentech, Inc. Variantes de l'inhibiteur c1 et traitement des reactions inflammatoires avec l'inhibiteur c1
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
PT1543106E (pt) 2002-07-15 2007-05-31 Immunex Corp Métodos e meios para controlar a sialilação de proteínas produzidas por células de mamíferos
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
CN101035568A (zh) * 2004-08-03 2007-09-12 比奥雷克西斯技术股份有限公司 使用包含glp－1的运铁蛋白融合蛋白的组合治疗
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
WO2006130834A2 (fr) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System Molecules d'immunoglobuline ayant des proprietes ameliorees
EP4155385A1 (fr) 2005-12-08 2023-03-29 Amgen Inc. Production amelioree de glycoproteines utilisant le manganese
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
EP2059527B1 (fr) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Glycoprotéines modifiées
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
EP2930245B1 (fr) 2007-10-12 2017-11-22 Sigma-Aldrich Co. LLC Lignée cellulaire et procédés pour une sialylation améliorée des glycoprotéines
MY161892A (en) 2008-02-19 2017-05-15 Biocon Ltd A method of obtaining a purified, biologically active heterologous protein
EP2166085A1 (fr) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Cellules modifiées bivalentes
CN102317309A (zh) 2009-02-26 2012-01-11 巴特勒能源同盟有限公司 通过不同的翻译后修饰改变和调节蛋白质活性
MX340971B (es) 2009-11-23 2016-08-02 Amgen Inc * Fragmento cristalizable (fc) de anticuerpo monomerico.
US10435458B2 (en) * 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
WO2011116291A1 (fr) * 2010-03-18 2011-09-22 Thrombolytic Science International Production d'un inhibiteur du c1 humain dans des cellules humaines
US20120010013A1 (en) * 2010-06-19 2012-01-12 Fellows Edwin E Swing assistant device
EP2603526A1 (fr) 2010-08-13 2013-06-19 Medimmune Limited Polypeptides monomères comprenant des régions du variant fc et procédés d'utilisation de ceux-ci
WO2012083370A1 (fr) * 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Anticorps modifié présentant une demi-vie améliorée
WO2012107572A1 (fr) 2011-02-10 2012-08-16 Leiden University Medical Center Procédé de purification d'un glycane et/ou d'un glycoconjugué par chromatographie au moyen d'une phase stationnaire comprenant du coton
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
HUE041335T2 (hu) * 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
IL312872A (en) * 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
JP6280499B2 (ja) 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｆｃ融合タンパク質の精製方法
CN102890790B (zh) * 2011-07-22 2014-04-30 鸿富锦精密工业（深圳）有限公司 扩展卡
WO2013093760A2 (fr) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, procédés et trousses pour la préparation de protéines recombinantes sialylées
KR102022231B1 (ko) * 2011-12-22 2019-09-19 체에스엘 베링 게엠베하 중추 신경계의 2차 부종을 치료하기 위한 ｃ1-억제제의 용도
EP2623110A1 (fr) * 2012-01-31 2013-08-07 CSL Behring GmbH Inhibiteurs de facteur XII pour le traitement de troubles inflammatoires neurologiques
EP2825557B1 (fr) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Fc monomère modifié soluble
EP2928917B1 (fr) 2012-12-07 2018-02-28 Pfizer Inc Fragments d'anticorps monomérique génétiquement modifié
US10286047B2 (en) * 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US20160184458A1 (en) * 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
EP2796145B1 (fr) * 2013-04-22 2017-11-01 CSL Ltd. Un complexe covalent de facteur von willebrand et de faktor viii conjugé par un pont disulfure

Also Published As

Publication number Publication date
JP2020202841A (ja) 2020-12-24
CN107108753A (zh) 2017-08-29
JP6740225B2 (ja) 2020-08-12
EP3769780A1 (fr) 2021-01-27
CA2964132A1 (fr) 2016-05-06
US20160130324A1 (en) 2016-05-12
AU2021200977A1 (en) 2021-03-11
JP2018503355A (ja) 2018-02-08
WO2016070156A3 (fr) 2016-06-23
EP3212663B1 (fr) 2020-05-27
WO2016070156A2 (fr) 2016-05-06
HK1243443A1 (zh) 2018-07-13
KR20240035643A (ko) 2024-03-15
BR112017008962A2 (pt) 2018-01-16
AU2015338913B2 (en) 2020-11-19
JP2023027290A (ja) 2023-03-01
EP3212663A2 (fr) 2017-09-06
AU2015338913A1 (en) 2017-05-04
KR20170074244A (ko) 2017-06-29
CN113698495A (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA44986A (fr) Protéines de fusion gdf15 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
KR20180084895A (ko) 효소 내재화 조성물 및 방법
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA53991A (fr) Protéines de fusion de l'inhibiteur de la c1 estérase et leurs utilisations
MA43552A (fr) Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
DK3292141T3 (da) Fusionsproteiner
KR20180084749A (ko) 멀티뷰 디스플레이 및 관련 시스템과 방법
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
MA43567A (fr) Anticorps pacap et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels